MarketCap
Nektar Therapeutics NKTR
$ 38.41
1.56%
Facebook
X
Telegram
Nektar Therapeutics DSO Ratio | NKTR
Annual DSO Ratio Nektar Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.23 | 14.6 | 56.4 | 110 | 90.3 | 117 | 13.2 | 5.95 | 34.6 | 31.5 | 6.56 | 5.46 | 26.1 | 25.2 | 28.8 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 117 | 2.23 | 37.9 |
Quarterly DSO Ratio Nektar Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2.26 | 9.35 | 12.3 | 6.69 | 9.64 | 6.33 | - | 22.3 | - | 96.9 | 93.9 | 106 | 93.5 | 131 | 151 | 118 | 72.7 | 68.3 | 99.2 | 115 | 144 | 129 | 64.5 | 92.5 | 3.63 | 57.9 | 4.79 | 2.99 | 13.2 | 38.2 | 38.2 | 39.4 | 43.7 | 27.6 | 46.2 | 30.4 | 80.3 | 9.88 | 16.8 | 2.48 | 11.5 | 13.5 | 6.53 | 3.34 | 6.01 | 15.9 | 25.1 | 28.8 | 22.4 | 27.3 | 28.6 | 16.6 | 26 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 151 | 2.26 | 45.7 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
CorMedix
CRMD
|
130 | $ 5.31 | -2.23 % | $ 383 K |  USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.3 K | $ 45.39 | 0.53 % | $ 4.08 B |  Schweiz |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
65.6 | $ 1.66 | -2.64 % | $ 1.12 B |  Israel |
 |
Deciphera Pharmaceuticals
DCPH
|
60.8 | - | - | $ 2.18 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
158 | - | -23.04 % | $ 26.6 M | USA |
 |
Verona Pharma plc
VRNA
|
136 | - | - | $ 69.7 B |  Britain |
 |
Karuna Therapeutics
KRTX
|
15.9 | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
64.7 | $ 0.59 | -9.62 % | $ 7.77 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
137 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Fusion Pharmaceuticals
FUSN
|
6 | - | - | $ 1.41 B |  Canada |
 |
Gritstone Oncology
GRTS
|
40.3 | - | 0.42 % | $ 213 M | USA |
 |
Pfizer
PFE
|
68.1 | $ 29.42 | 0.19 % | $ 167 B | USA |
 |
HOOKIPA Pharma
HOOK
|
3.33 | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
62.6 | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
84.9 | - | - | $ 109 M | USA |
 |
Otonomy
OTIC
|
32.1 | - | -1.96 % | $ 4.68 M | USA |
 |
Prothena Corporation plc
PRTA
|
6.97 | $ 8.74 | 2.1 % | $ 470 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 70.73 | 0.21 % | $ 19.2 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Фармсинтез
LIFE
|
209 | - | - | - |  Russia |
 |
Arcus Biosciences
RCUS
|
3.21 | $ 18.83 | 0.86 % | $ 2.02 B | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
120 | $ 14.79 | -0.57 % | $ 12.3 B |  India |
 |
Oncternal Therapeutics
ONCT
|
20.6 | - | -24.12 % | $ 1.56 M | USA |
 |
Iterum Therapeutics
ITRM
|
740 | - | - | $ 591 K |  Irlanda |
 |
Rhythm Pharmaceuticals
RYTM
|
42.9 | $ 114.06 | 0.1 % | $ 7.41 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | USA |
 |
SIGA Technologies
SIGA
|
47.1 | $ 3.17 | 0.32 % | $ 227 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
5.06 | - | - | $ 401 M | USA |
 |
ImmunoGen
IMGN
|
121 | - | - | $ 7.92 B | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
114 | - | -8.77 % | $ 12.4 M | Israel |
 |
Histogen
HSTO
|
12.8 | - | 31.6 % | $ 2.12 M | USA |
 |
Summit Therapeutics
SMMT
|
469 | $ 16.64 | -6.7 % | $ 12.4 B | Britain |
 |
Checkpoint Therapeutics
CKPT
|
6.83 | - | - | $ 169 M | USA |
 |
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | USA |
 |
Syndax Pharmaceuticals
SNDX
|
48.3 | $ 9.59 | 1.05 % | $ 831 M | USA |
 |
Scholar Rock Holding Corporation
SRRK
|
445 | $ 46.66 | -2.8 % | $ 5.35 B | USA |
 |
Clovis Oncology
CLVS
|
271 | - | -7.23 % | $ 13 M | USA |